利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.009 秒)

    Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations
    1.
    发明公开
    Compositions and the use of interleukin-2 and/or interferon-beta and tumour necrosis factor for combination therapy or in providing medicaments or formulations 失效
    组合物和使用白介素-2和/或干扰素-β和肿瘤坏死因子的组合治疗或用于药物或制剂的制备。

    公开(公告)号：EP0248516A1

    公开(公告)日：1987-12-09

    申请号：EP87303120.7

    申请日：1987-04-09

    申请人： CETUS CORPORATION

    发明人： Winkelhake, Jeffrey Lee ,  Zimmerman, Robert

    IPC分类号： A61K37/02 ,  A61K37/66

    CPC分类号： A61K38/2013 ,  A61K38/215 ,  A61K38/191 ,  A61K2300/00

    摘要： Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-β, or of TNF, IL-2 and IFN-β in combination. The composition of TNF and IL-2 and/or IFN-p may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, and lymphoma.

    摘要翻译： 在哺乳动物中的抗肿瘤活性可以通过给予所述哺乳动物宿主协同有效量的TNF和IL-2的TNF或IFN和-β来增强，或TNF，IL-2和ITN的β组合。 TNF和IL-2和/或IFN-β的组​​合物可在体外制备或单独地施用给宿主。 如果TNF和IL-2被依次施用，所述TNF必须在IL-2之前给药以获得协同作用。 该组合物用于治疗如检查肥大细胞瘤，黑色素瘤，白血病，和淋巴瘤的癌症。

    Anti-human ovarian cancer immunotoxins and methods of use thereof
    3.
    发明公开
    Anti-human ovarian cancer immunotoxins and methods of use thereof 失效
    抗人卵巢癌免疫毒素及其使用方法

    公开(公告)号：EP0226418A3

    公开(公告)日：1988-04-27

    申请号：EP86309515

    申请日：1986-12-05

    申请人： CETUS CORPORATION

    发明人： Bjorn, Michael Jon ,  Frankel, Arthur Edward ,  Laird, Walter Joseph ,  Ring, David Barratt ,  Winkelhake, Jeffrey Lee

    IPC分类号： A61K47/00 ,  A61K37/02 ,  A61K35/74

    CPC分类号： C07K16/30 ,  A61K38/00 ,  A61K47/6869

    摘要： Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab') 2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID 50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the (F(ab') 2 region of the antitransferrin monoclonal antibody are also claimed. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian tumors in mammals and extending the survival of mammals carrying human ovarian tumors are claimed.

    摘要翻译： 要求保护包含细胞毒性部分和选自Fab，Fab'和F（ab'）2单克隆抗体片段的抗原结合部分的免疫毒素，其结合人卵巢癌组织，具有以下能力之一： 对人卵巢癌细胞的约10nM或更低的细胞毒性ID50，在哺乳动物中延迟人卵巢癌肿瘤生长或携带人卵巢癌肿瘤的哺乳动物的存活延长。 鉴定单克隆抗体结合的抗原或表位，并表征免疫毒素。 在一个优选实施方案中，描述并要求保护包含至少一个单克隆抗体的抗原结合部分的免疫毒素，其结合人转铁蛋白受体但不阻断转铁蛋白与受体的结合。 要求保护包含抗转铁蛋白单克隆抗体（F（ab'）2区域的免疫毒素。）要求保护杀死人卵巢癌细胞，延缓哺乳动物中人卵巢肿瘤生长和延长携带人卵巢肿瘤的哺乳动物存活的方法。